Q1 · MEDICINE
Article
Author: Cao, Wenyue ; Wang, Gaoxiang ; Zhang, Tongcun ; Huang, Liang ; Li, Chunrui ; Zhou, Xiaoxi ; Cai, Haodong ; Wang, Na ; Hu, Xuelian ; Yan, Dandan ; Zhang, Shangkun ; Lou, Yaoyao ; Zhang, Yicheng ; Cheng, Jiali ; Jiang, Lijun ; Chen, Liting ; Xiao, Yi ; Zheng, Miao ; Gu, Chaojiang ; Cao, Yang ; Wang, Qiuxiang ; Mao, Xia ; Zhou, Jianfeng ; Wang, Di
Relapse following chemeric antigen receptor (CAR) T-cell therapy can arise from progressive loss of the CAR T cells or from loss of the target antigen by tumor cells. Wang et al report that using a mix of CAR T cells targeting CD19 and CD22 reduces relapse with antigen-negative tumor cells. However, a lack of CAR T-cell persistence leads to increased relapse with antigen-positive cells.